- Home
- VRDN
as 11-15-2024 4:00pm EST
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 1.5B | IPO Year: | N/A |
| Target Price: | $37.25 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.40 - $27.20 | Next Earning Date: | 11-12-2024 |
| Revenue: | $302,000 | Revenue Growth: | -12.97% |
| Revenue Growth (this year): | -8.35% | Revenue Growth (next year): | -10.88% |
Stock Insider Trading Activity of Viridian Therapeutics Inc. (VRDN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Beetham Thomas W. | VRDN | Chief Operating Officer | Sep 27 '24 | Buy | $23.41 | 5,000 | $117,050.00 | 6,000 | |
| Mahoney Stephen F. | VRDN | President and CEO | Sep 27 '24 | Buy | $23.33 | 21,400 | $499,262.00 | 21,400 | |
| Fairmount Funds Management LLC | VRDN | Director10% Owner | Sep 13 '24 | Buy | $18.75 | 1,600,000 | $30,000,000.00 | 3,445,813 |
Latest Viridian Therapeutics Inc. News
VRDN Breaking Stock News: Dive into VRDN Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
Viridian Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Business Wire
5 days ago
Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data
Business Wire
12 days ago
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
17 days ago
Viridian Therapeutics Insiders Added US$616.3k Of Stock To Their Holdings
Argus Research
2 months ago
Daily – Vickers Top Buyers & Sellers for 10/01/2024
Business Wire
2 months ago
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
Business Wire
2 months ago
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
Business Wire
2 months ago
Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
Compare VRDN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRDN Viridian Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.